"10.1371_journal.pone.0085400","plos one","2014-01-08T00:00:00Z","Riva Kovjazin; Galit Horn; Nechama I Smorodinsky; Michael Y Shapira; Lior Carmon","Vaxil BioTherapeutics Ltd., Weizmann Science Park, Nes-Ziona, Israel; Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel; The Alec and Myra Marmot Hybridoma Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel","Conceived and designed the experiments: RK NIS LC. Performed the experiments: RK GH MYS. Analyzed the data: RK GH MYS LC. Contributed reagents/materials/analysis tools: NIS MYS. Wrote the paper: LC. Prepared data: RK GH.","The authors have read the journals policy and have the following conflicts: Lior Carmon is the founder and CEO and Riva Kovjazin, and is a senior scientist of Vaxil BioTherapeutics Ltd., a start-up company which is developing ImMucin, an anti-MUC1 SP therapeutic vaccine against MUC1-positive tumors. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The other authors declare no conflict of interest.","2014","01","Riva Kovjazin","RK",5,TRUE,3,3,4,1,TRUE,TRUE,FALSE,0,NA,FALSE
